The most commonly used BRAF inhibitor among patients with BRAF-altered CRC was encorafenib in 85%, whereas the most common BRAF inhibitor in those with a BRAF-altered non-CRC GI malignancy was dabrafenib in 91%. Here, BRAF is linked to colorectal carcinoma.